These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24327540)

  • 21. Use of enthalpy and Gibbs free energy to evaluate the risk of amorphous formation.
    Hsieh DS; Sarsfield BA; Davidovich M; DiMemmo LM; Chang SY; Kiang S
    J Pharm Sci; 2010 Sep; 99(9):4096-105. PubMed ID: 20564337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.
    Shah B; Kakumanu VK; Bansal AK
    J Pharm Sci; 2006 Aug; 95(8):1641-65. PubMed ID: 16802362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spontaneous crystallinity loss of drugs in the disordered regions of poly(ethylene oxide) in the presence of water.
    Marsac PJ; Romary DP; Shamblin SL; Baird JA; Taylor LS
    J Pharm Sci; 2008 Aug; 97(8):3182-94. PubMed ID: 18000812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.
    Healy AM; Worku ZA; Kumar D; Madi AM
    Adv Drug Deliv Rev; 2017 Aug; 117():25-46. PubMed ID: 28342786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation.
    Airaksinen S; Karjalainen M; Kivikero N; Westermarck S; Shevchenko A; Rantanen J; Yliruusi J
    AAPS PharmSciTech; 2005 Oct; 6(2):E311-22. PubMed ID: 16353990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using DVS-NIR to assess the water sorption behaviour and stability of a griseofulvin/PVP K30 solid dispersion.
    Li W; Buckton G
    Int J Pharm; 2015 Nov; 495(2):999-1004. PubMed ID: 26456266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance.
    Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M
    J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyphenation of Raman spectroscopy with gravimetric analysis to interrogate water-solid interactions in pharmaceutical systems.
    Gift AD; Taylor LS
    J Pharm Biomed Anal; 2007 Jan; 43(1):14-23. PubMed ID: 16882458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate.
    Van Gyseghem E; Stokbroekx S; de Armas HN; Dickens J; Vanstockem M; Baert L; Rosier J; Schueller L; Van den Mooter G
    Eur J Pharm Sci; 2009 Dec; 38(5):489-97. PubMed ID: 19782132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery.
    Al-Obaidi H; Majumder M; Bari F
    Curr Pharm Des; 2017; 23(3):350-361. PubMed ID: 27829335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-situ determination of crystallization kinetics in ASDs via water sorption experiments.
    Luebbert C; Sadowski G
    Eur J Pharm Biopharm; 2018 Jun; 127():183-193. PubMed ID: 29477357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microcalorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids.
    Lechuga-Ballesteros D; Bakri A; Miller DP
    Pharm Res; 2003 Feb; 20(2):308-18. PubMed ID: 12636173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of hydrate-screening methods.
    Cui Y; Yao E
    J Pharm Sci; 2008 Jul; 97(7):2730-44. PubMed ID: 17914731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid state amorphization of pharmaceuticals.
    Willart JF; Descamps M
    Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
    Lu J; Rohani S
    Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Excipient Interactions in the Solid State: The Role of Different Stress Factors.
    Gressl C; Brunsteiner M; Davis A; Landis M; Pencheva K; Scrivens G; Sluggett GW; Wood GPF; Gruber-Woelfler H; Khinast JG; Paudel A
    Mol Pharm; 2017 Dec; 14(12):4560-4571. PubMed ID: 29058913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.